Advertisement
Loading...

Geron Corporation

GERNNASDAQ
Healthcare
Biotechnology
$1.28
$0.02(1.59%)
U.S. Market is Open • 09:44
Advertisement

Geron Corporation Fundamental Analysis

Geron Corporation (GERN) shows weak financial fundamentals with a PE ratio of -12.31, profit margin of -35.48%, and ROE of -28.90%. The company generates $0.2B in annual revenue with weak year-over-year growth of 1.39%.

Key Strengths

Cash Position36.68%
PEG Ratio-0.18
Current Ratio6.78

Areas of Concern

ROE-28.90%
Operating Margin-19.05%
We analyze GERN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -16.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-16.8/100

We analyze GERN's fundamental strength across five key dimensions:

Efficiency Score

Weak

GERN struggles to generate sufficient returns from assets.

ROA > 10%
-13.03%

Valuation Score

Excellent

GERN trades at attractive valuation levels.

PE < 25
-12.31
PEG Ratio < 2
-0.18

Growth Score

Moderate

GERN shows steady but slowing expansion.

Revenue Growth > 5%
1.39%
EPS Growth > 10%
51.85%

Financial Health Score

Moderate

GERN shows balanced financial health with some risks.

Debt/Equity < 1
1.10
Current Ratio > 1
6.78

Profitability Score

Weak

GERN struggles to sustain strong margins.

ROE > 15%
-2889.85%
Net Margin ≥ 15%
-35.48%
Positive Free Cash Flow
No

Key Financial Metrics

Is GERN Expensive or Cheap?

P/E Ratio

GERN trades at -12.31 times earnings. This suggests potential undervaluation.

-12.31

PEG Ratio

When adjusting for growth, GERN's PEG of -0.18 indicates potential undervaluation.

-0.18

Price to Book

The market values Geron Corporation at 3.74 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.74

EV/EBITDA

Enterprise value stands at -15.73 times EBITDA. This is generally considered low.

-15.73

How Well Does GERN Make Money?

Net Profit Margin

For every $100 in sales, Geron Corporation keeps $-35.48 as profit after all expenses.

-35.48%

Operating Margin

Core operations generate -19.05 in profit for every $100 in revenue, before interest and taxes.

-19.05%

ROE

Management delivers $-28.90 in profit for every $100 of shareholder equity.

-28.90%

ROA

Geron Corporation generates $-13.03 in profit for every $100 in assets, demonstrating efficient asset deployment.

-13.03%

Following the Money - Real Cash Generation

Operating Cash Flow

Geron Corporation generates limited operating cash flow of $-120.72M, signaling weaker underlying cash strength.

$-120.72M

Free Cash Flow

Geron Corporation generates weak or negative free cash flow of $-121.04M, restricting financial flexibility.

$-121.04M

FCF Per Share

Each share generates $-0.19 in free cash annually.

$-0.19

FCF Yield

GERN converts -15.38% of its market value into free cash.

-15.38%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-12.31

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.18

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.74

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.19

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

6.78

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.29

vs 25 benchmark

ROA

Return on assets percentage

-0.13

vs 25 benchmark

ROCE

Return on capital employed

-0.08

vs 25 benchmark

How GERN Stacks Against Its Sector Peers

MetricGERN ValueSector AveragePerformance
P/E Ratio-12.3129.06 Better (Cheaper)
ROE-28.90%733.00% Weak
Net Margin-35.48%-53111.00% (disorted) Weak
Debt/Equity1.100.38 Weak (High Leverage)
Current Ratio6.784.02 Strong Liquidity
ROA-13.03%-19397.00% (disorted) Weak

GERN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Geron Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

29494.86%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

53.81%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

32.16%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ